Clinical Trials
12 trialsNCT06500273 2026-06-02
ALPHA3
Allogene Therapeutics
Phase 2 Recruiting
NCT06358430 2026-05-20
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03192397 2026-04-14
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Phase 1/2 Active not recruiting
NCT05735717 2026-04-06
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT05987696 2026-02-11
Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Completed
NCT04991103 2025-12-31
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
Phase 2 Recruiting
NCT07301138 2025-12-24
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
Ruijin Hospital
Phase 2 Not yet recruiting
NCT02666898 2025-11-26
ICLL07GAI
French Innovative Leukemia Organisation
Phase 2 Completed
NCT03233854 2025-11-18
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
Stanford University
Phase 1 Active not recruiting
NCT01898039 2025-10-02
Modified Vaccine for High Risk or Low Residual Melanoma Patients
Hadassah Medical Organization
Phase 1/2 Recruiting
NCT02159495 2025-09-16
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03241940 2025-06-29
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
Stanford University
Phase 1 Active not recruiting